Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RFC1-related disorders: A case series of 4-aminopyridine and acetyl-DL-leucine treatment.

Cerebellum (London, England)·2026
Same author

Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far.

Frontiers in psychiatry·2026
Same author

Human <i>in vivo</i> assessment of ketamine binding of the serotonin transporter-follow up at a higher dose.

Frontiers in neuroscience·2025
Same author

Genetic predisposition to unwanted side effects under antidepressants and antipsychotics: a molecular-genetic study of 902 patients over 6 weeks.

European archives of psychiatry and clinical neuroscience·2025
Same author

Contribution of Rare and Potentially Functionally Relevant Sequence Variants in Schizophrenia Risk-Locus Xq28,distal.

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics·2024
Same author

Morphological correlates of anxiety-related experiences during a ketamine infusion.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2024
Same journal

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry·2026
Same journal

A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis.

Pharmacopsychiatry·2026
Same journal

High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting.

Pharmacopsychiatry·2026
Same journal

Great Expectations, Limited Evidence: The Emerging Role of Artificial Intelligence in Pharmacopsychiatry.

Pharmacopsychiatry·2026
Same journal

Rates of Hypoprolactinemia in Bipolar Patients Receiving Once-monthly Long-acting Injectable Aripiprazole.

Pharmacopsychiatry·2026
Same journal

Clinical and Neurobiological Findings in a Patient With Unipolar Depressive 48-hour-ultrarapid-cycling.

Pharmacopsychiatry·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

Pharmacopsychiatry. Editorial

F Tretter, D Rujescu, C W Turck

    Pharmacopsychiatry
    |May 6, 2011
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
    07:02

    A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

    Published on: February 11, 2019

    Related Experiment Videos

    Last Updated: Jun 2, 2026

    Intracranial Pharmacotherapy and Pain Assays in Rodents
    02:26

    Intracranial Pharmacotherapy and Pain Assays in Rodents

    Published on: April 9, 2019

    A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
    07:02

    A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

    Published on: February 11, 2019